$ATEX

Fleischhauer Mark sold $279K of ATEX

Fleischhauer Mark sold 3,500 shares of Anterix Inc. (ATEX) at $79.83 ($0.28M total) on 2026-06-15.

Original reporting
SEC EDGAR · Fleischhauer Mark
Published Jun 17, 2026, 11:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATEX
Neutral
high confidence
Mentioned
$ATEX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 3,500 shares at ~$79.8294 on 2026-06-15, with holdings after the sale of 12,769 shares.

02

Market read

This is a routine insider-sale filing; it may slightly influence sentiment but lacks fundamental company catalysts in the text.

03

What to watch

Traders may want to check whether other insiders sold/bought around the same period and whether the director’s remaining holdings changed materially versus prior filings.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-17; transaction dated 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Anterix Inc. (ATEX).

Company-level read

Ticker impact

$ATEXNeutralHigh confidence
Context

Anterix director Mark Fleischhauer sold 3,500 ATEX shares in an open-market transaction on 2026-06-15 for ~$279.4K.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with broader insider activity or material company news.

Evidence & confidence

The filing is a standard SEC Form 4 insider transaction with no 10b5-1 plan and no accompanying fundamental catalyst in the text.

Market effects

Minimal; single insider sale does not change sector fundamentals based on the provided text.

None indicated.

None indicated.

Counterpoint

No 10b5-1 plan is noted, but the sale could be for diversification/tax rather than a bearish view; one transaction is not a trend.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider transaction; director Mark Fleischhauer sold shares.

  • Mark Fleischhauer

    Director who executed the open-market sale; no pre-arranged 10b5-1 plan indicated.

Related articles

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2